Use of cardiac biomarkers in end-stage renal disease

167Citations
Citations of this article
106Readers
Mendeley users who have this article in their library.

Abstract

Mortality among patients with ESRD remains high because of an excessive cardiovascular risk related to a very high incidence of cardiac hypertrophy, cardiomyopathy, heart failure, and coronary artery disease. Identifying serum biomarkers that are useful in profiling cardiovascular risk and enabling stratification of early mortality and cardiovascular risk is an important goal in the treatment of these patients. This review examines current evidence pertaining to the role and utility of two emerging cardiac biomarkers, B-type natriuretic peptide and cardiac troponin T, in patients with ESRD. Together, these data demonstrate how these two cardiac biomarkers may play an adjunctive role to echocardiography in assessing cardiovascular risk and how they may aid in the clinical treatment of these patients.

Cite

CITATION STYLE

APA

Wang, A. Y. M., & Lai, K. N. (2008). Use of cardiac biomarkers in end-stage renal disease. Journal of the American Society of Nephrology. American Society of Nephrology. https://doi.org/10.1681/ASN.2008010012

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free